MYCOF — Mydecine Innovations Share Price
Last trade - 00:00- $0.63m
- $4.62m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.21 | 0.28 | 0 | 0.01 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 27th, 2013
- Public Since
- August 18th, 2014
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 58,127,177
- Address
- 1890-1075 West Georgia Street, VANCOUVER, V6E 3C9
- Web
- https://www.mydecine.com/
- Phone
- +1 6046872038
- Auditors
- BF Borgers CPA PC
Latest News for MYCOF
Upcoming Events for MYCOF
Q4 2023 Mydecine Innovations Group Inc Earnings Release
Mydecine Innovations Group Inc Annual Shareholders Meeting
Q1 2024 Mydecine Innovations Group Inc Earnings Release
Q2 2024 Mydecine Innovations Group Inc Earnings Release
Similar to MYCOF
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:14 UTC, shares in Mydecine Innovations are trading at $0.01. This share price information is delayed by 15 minutes.
Shares in Mydecine Innovations last closed at $0.01 and the price had moved by -97.98% over the past 365 days. In terms of relative price strength the Mydecine Innovations share price has underperformed the S&P500 Index by -98.27% over the past year.
The overall consensus recommendation for Mydecine Innovations is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Mydecine Innovations does not currently pay a dividend.
Mydecine Innovations does not currently pay a dividend.
Mydecine Innovations does not currently pay a dividend.
To buy shares in Mydecine Innovations you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.01, shares in Mydecine Innovations had a market capitalisation of $0.63m.
Here are the trading details for Mydecine Innovations:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MYCOF
Based on an overall assessment of its quality, value and momentum Mydecine Innovations is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mydecine Innovations. Over the past six months, its share price has underperformed the S&P500 Index by -91.67%.
As of the last closing price of $0.01, shares in Mydecine Innovations were trading -86.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mydecine Innovations PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Mydecine Innovations' directors